Literature DB >> 33011137

Monocyte phenotyping and management of lipoprotein X syndrome.

Zeqin Lian1, Anum Saeed2, Xueying Peng3, Xiaoyuan Dai Perrard1, Xiaoming Jia4, Aliza Hussain4, Christie M Ballantyne5, Huaizhu Wu6.   

Abstract

BACKGROUND: Accumulation of lipoprotein X (LpX) in blood can cause severe hypercholesterolemia and cutaneous xanthomas. Monocytes sensitively sense lipid changes in circulation and contribute to inflammation. However, how monocytes respond to LpX is undefined.
OBJECTIVE: We examined the phenotype of monocytes from a patient, who had LpX, severe hypercholesterolemia, and extensive cutaneous xanthomas, and effects of semiselective plasmapheresis therapy (SPPT).
METHOD: Fluorescence-activated cell sorting and adhesion assays were used to examine monocyte phenotype and ex vivo oxidized low-density lipoprotein uptake and adhesion in the patient before and after treatment with SPPT. Effects of plasma from the patient on the phenotype and adhesion of monocytes from a healthy participant were determined.
RESULTS: SPPT improved hypercholesterolemia and cutaneous xanthomas. Before treatment, the patient had lower frequency of nonclassical monocytes but higher frequency of intermediate monocytes than the control participant. Before treatment, monocytes from the patient with LpX showed more intracellular lipid accumulation, alterations in several cell surface markers and intracellular cytokines, as well as enhanced oxidized low-density lipoprotein uptake and reduced adhesion compared with control. After SPPT, the phenotypes of monocytes from the patient with LpX were similar to control monocytes. Incubation with plasma from the patient before treatment as compared with plasma from the control participant or the patient after treatment increased CD11c expression and adhesion of monocytes from a healthy participant.
CONCLUSION: LpX-induced hypercholesterolemia increased lipid accumulation and altered the phenotype of monocytes, which may contribute to cutaneous xanthoma development. Removal of LpX by SPPT reduced lipid accumulation and improved monocyte phenotype, likely contributing to xanthoma resolution.
Copyright © 2020 National Lipid Association. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Foamy monocyte; Hypercholesterolemia; Lipoprotein X; Primary biliary cirrhosis

Mesh:

Substances:

Year:  2020        PMID: 33011137      PMCID: PMC7736232          DOI: 10.1016/j.jacl.2020.08.012

Source DB:  PubMed          Journal:  J Clin Lipidol        ISSN: 1876-4789            Impact factor:   4.766


  19 in total

Review 1.  Lipoprotein-X fifty years after its original discovery.

Authors:  R Fellin; E Manzato
Journal:  Nutr Metab Cardiovasc Dis       Date:  2018-09-26       Impact factor: 4.222

2.  Lipoproteins in LCAT-deficiency.

Authors:  G Utermann; W Schoenborn; K H Langer; P Dieker
Journal:  Humangenetik       Date:  1972

3.  Lipoprotein-X in cholestatic patients causes xanthomas and promotes foam cell formation in human macrophages.

Authors:  Luka Suzuki; Satoshi Hirayama; Mariko Fukui; Makoto Sasaki; Sadayuki Hiroi; Makoto Ayaori; Shuji Terai; Minoru Tozuka; Hirotaka Watada; Takashi Miida
Journal:  J Clin Lipidol       Date:  2016-11-05       Impact factor: 4.766

4.  Postprandial Monocyte Activation in Individuals With Metabolic Syndrome.

Authors:  Ilvira M Khan; Yashashwi Pokharel; Razvan T Dadu; Dorothy E Lewis; Ron C Hoogeveen; Huaizhu Wu; Christie M Ballantyne
Journal:  J Clin Endocrinol Metab       Date:  2016-08-30       Impact factor: 5.958

5.  Low density lipoprotein oxidized in xanthoma tissue induces the formation and infiltration of foam cells.

Authors:  Yasuhiko Hirata; Kozo Okawa; Mitsunori Ikeda; Masahiro Seike; Masaaki Matsumoto; Hajime Kodama
Journal:  J Dermatol Sci       Date:  2002-12       Impact factor: 4.563

6.  A lipoprotein characterizing obstructive jaundice. II. Isolation and partial characterization of the protein moieties of low density lipoproteins.

Authors:  D Seidel; P Alaupovic; R H Furman; W J McConathy
Journal:  J Clin Invest       Date:  1970-12       Impact factor: 14.808

7.  Management of lipoprotein X and its complications in a patient with primary sclerosing cholangitis.

Authors:  Eric J Brandt; Shane M Regnier; Edward Ky Leung; Sharon H Chou; Beverly W Baron; Helen S Te; Michael H Davidson; Robert M Sargis
Journal:  Clin Lipidol       Date:  2015-08-01

8.  PCSK9 monoclonal antibodies reverse the pro-inflammatory profile of monocytes in familial hypercholesterolaemia.

Authors:  Sophie J Bernelot Moens; Annette E Neele; Jeffrey Kroon; Fleur M van der Valk; Jan Van den Bossche; Marten A Hoeksema; Renate M Hoogeveen; Johan G Schnitzler; Marie T Baccara-Dinet; Garen Manvelian; Menno P J de Winther; Erik S G Stroes
Journal:  Eur Heart J       Date:  2017-05-21       Impact factor: 29.983

9.  Detection of Lipoprotein X (LpX): A challenge in patients with severe hypercholesterolaemia.

Authors:  Agnieszka Ćwiklińska; Agnieszka Mickiewicz; Robert Kowalski; Barbara Kortas-Stempak; Agnieszka Kuchta; Krzysztof Mucha; Michał Makowiecki; Anna Gliwińska; Krzysztof Lewandowski; Leszek Pączek; Marcin Fijałkowski; Marcin Gruchała; Maciej Jankowski
Journal:  J Med Biochem       Date:  2020-09-02       Impact factor: 3.402

10.  Triglyceride-Rich Lipoproteins Modulate the Distribution and Extravasation of Ly6C/Gr1(low) Monocytes.

Authors:  Maha F Saja; Lucie Baudino; William D Jackson; H Terence Cook; Talat H Malik; Liliane Fossati-Jimack; Marieta Ruseva; Matthew C Pickering; Kevin J Woollard; Marina Botto
Journal:  Cell Rep       Date:  2015-09-03       Impact factor: 9.423

View more
  1 in total

1.  When LDL Cholesterol Is Not LDL Cholesterol: LpX, A Clinical Lesson.

Authors:  Lisa P M Huygen; Jan Westerink; Gerben C Mol; Remy H H Bemelmans
Journal:  JACC Case Rep       Date:  2022-06-01
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.